Back to Search
Start Over
Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study
- Source :
- The Lancet Gastroenterology & Hepatology; June 2022, Vol. 7 Issue: 6 p522-532, 11p
- Publication Year :
- 2022
-
Abstract
- Immunotherapies have shown clinical activity in patients with advanced biliary tract cancer, for which outcomes remain poor despite standard of care treatment with gemcitabine and cisplatin. We aimed to evaluate gemcitabine and cisplatin plus durvalumab with or without tremelimumab as first-line treatment in patients with advanced biliary tract cancer.
Details
- Language :
- English
- ISSN :
- 24681253
- Volume :
- 7
- Issue :
- 6
- Database :
- Supplemental Index
- Journal :
- The Lancet Gastroenterology & Hepatology
- Publication Type :
- Periodical
- Accession number :
- ejs59630973
- Full Text :
- https://doi.org/10.1016/S2468-1253(22)00043-7